Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $107

SVB Leerink analyst Rick Bienkowski maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $112 to $107.
byBenzinga Newsdesk
August 8, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

SVB Leerink analyst Rick Bienkowski maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $112 to $107.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

This Analyst With 84% Accuracy Rate Boosts PT On Cracker Barrel; Here Are 5 Stock Picks For Last Week From Benzinga’s Most Accurate Analysts

By Lisa Levin
December 5, 8:19 AM
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst's opinion to trust.

APA